Active, not recruitingPhase 1NCT05462717
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Revolution Medicines, Inc.
- Principal Investigator
- Revolution Medicines, Inc.Revolution Medicines, Inc.
- Intervention
- RMC-6291(drug)
- Enrollment
- 222 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (30)
- Highlands Oncology Group, Springdale, Arkansas, United States
- UC Irvine Cancer Center, Orange, California, United States
- UC Davis Cancer Center, Sacramento, California, United States
- UCSF, San Francisco, California, United States
- University of Miami School of Medicine Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- American Oncology Partners of Maryland, Bethesda, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- MSK Cancer Center, New York, New York, United States
- Columbia University Irving Medical Center, New York, New York, United States
- Tennessee Oncology, Nashville, Tennessee, United States
- Next Oncology, San Antonio, Texas, United States
- START, San Antonio, Texas, United States
- Next Oncology Virginia, Fairfax, Virginia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05462717 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital